Technical Articles

Interleukin-13 is a core effector cytokine of type 2 immune responses, whose primary function is not to initiate immune reactions but to directly act on non-hematopoietic tissue cells, executing the terminal step of immune instructions—tissue remodeling.

In the intricate symphony of the human immune system, various cytokines act as precise conducting signals, coordinating the intensity and direction of immune responses. Among them, Interleukin-13 (IL-13), as a pivotal pleiotropic cytokine, has emerged as a central player in the study of type 2 immune responses and barrier tissue diseases.

Interleukin-13 is a core effector cytokine of type 2 immune responses, secreted by activated Th2 cells, type 2 innate lymphoid cells, and others.

IL-13 is a pleiotropic cytokine primarily produced by activated CD4+ Th2 cells, type 2 innate lymphoid cells, mast cells, and basophils, playing a central role in type 2 immune responses.

The mechanism by which IL-13 targeted therapy affects paradoxical erythema at the molecular level is still unclear, and further basic research is needed from the perspectives of immune microenvironment and receptor regulation.

Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by severe itching and eczema like skin lesions, which seriously affect the quality of life of patients. Its pathogenesis involves immune regulation abnormalities, among which interleukin-13 (IL-13) plays a central role in driving type 2 inflammatory response.

In Type 2 immune response-mediated allergic diseases, IL-4Rα serves as the shared subunit of interleukin-4 (IL-4) and interleukin-13 (IL-13) receptors, emerging as one of the most sought-after targets in the global biopharmaceutical sector. Through dual inhibition of IL-4/IL-13 signaling pathways, it has not only revolutionized therapeutic paradigms for conventional conditions like atopic dermatitis and asthma but also demonstrated remarkable potential across interdisciplinary fields including tumor immunology and viral infections.